Veradigm Valuation
Is MDRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MDRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MDRX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MDRX's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MDRX?
Key metric: As MDRX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is MDRX's PB Ratio? | |
|---|---|
| PB Ratio | n/a |
| Book | US$1.18b |
| Market Cap | US$1.81b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does MDRX's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.2x | ||
GDRX GoodRx Holdings | 2.4x | 48.0% | US$1.6b |
CERT Certara | 1.5x | 107.2% | US$1.6b |
NXGN NextGen Healthcare | 3.8x | 41.8% | US$1.6b |
TDOC Teladoc Health | 1x | 81.6% | US$1.6b |
MDRX Veradigm | n/a | 10.3% | US$1.8b |
Price-To-Book vs Peers: Insufficient data to calculate MDRX's Price-To-Book Ratio vs. peers for valuation analysis.
Price to Book Ratio vs Industry
How does MDRX's PB Ratio compare vs other companies in the US Healthcare Services Industry?
| 2 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: Insufficient data to calculate MDRX's Price-To-Book Ratio vs. industry for valuation analysis.
Price to Book Ratio vs Fair Ratio
What is MDRX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | n/a |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate MDRX's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$10.69 | US$12.75 +19.3% | 11.6% | US$15.00 | US$11.00 | n/a | 4 |
| Nov ’25 | US$9.26 | US$12.25 +32.3% | 15.7% | US$15.00 | US$10.00 | n/a | 4 |
| Oct ’25 | US$9.42 | US$12.25 +30.0% | 15.7% | US$15.00 | US$10.00 | n/a | 4 |
| Sep ’25 | US$9.95 | US$12.25 +23.1% | 15.7% | US$15.00 | US$10.00 | n/a | 4 |
| Aug ’25 | US$9.75 | US$12.25 +25.6% | 15.7% | US$15.00 | US$10.00 | n/a | 4 |
| Jul ’25 | US$9.50 | US$12.25 +28.9% | 15.7% | US$15.00 | US$10.00 | n/a | 4 |
| Jun ’25 | US$9.50 | US$12.25 +28.9% | 15.7% | US$15.00 | US$10.00 | n/a | 4 |
| May ’25 | US$7.82 | US$15.00 +91.8% | 42.9% | US$26.00 | US$10.00 | n/a | 4 |
| Apr ’25 | US$7.80 | US$15.00 +92.3% | 42.9% | US$26.00 | US$10.00 | n/a | 4 |
| Mar ’25 | US$6.13 | US$16.25 +165.1% | 35.7% | US$26.00 | US$11.00 | n/a | 4 |
| Feb ’25 | US$9.20 | US$14.33 +55.8% | 38.1% | US$26.00 | US$10.00 | n/a | 6 |
| Jan ’25 | US$10.49 | US$17.40 +65.9% | 32.6% | US$26.00 | US$11.00 | n/a | 5 |
| Dec ’24 | US$12.13 | US$18.40 +51.7% | 27.6% | US$26.00 | US$13.00 | n/a | 5 |
| Nov ’24 | US$13.33 | US$18.40 +38.0% | 27.6% | US$26.00 | US$13.00 | US$9.26 | 5 |
| Oct ’24 | US$13.14 | US$18.40 +40.0% | 27.6% | US$26.00 | US$13.00 | US$9.42 | 5 |
| Sep ’24 | US$13.52 | US$18.17 +34.4% | 25.7% | US$26.00 | US$13.00 | US$9.95 | 6 |
| Aug ’24 | US$13.38 | US$18.64 +39.3% | 24.0% | US$26.00 | US$13.00 | US$9.75 | 7 |
| Jul ’24 | US$12.60 | US$18.08 +43.5% | 25.5% | US$26.00 | US$13.00 | US$9.50 | 6 |
| Jun ’24 | US$11.89 | US$18.79 +58.0% | 23.5% | US$26.00 | US$13.00 | US$9.50 | 7 |
| May ’24 | US$12.53 | US$19.19 +53.1% | 22.2% | US$26.00 | US$13.00 | US$7.82 | 8 |
| Apr ’24 | US$13.05 | US$20.07 +53.8% | 18.9% | US$26.00 | US$13.00 | US$7.80 | 7 |
| Mar ’24 | US$14.49 | US$20.64 +42.5% | 14.0% | US$26.00 | US$17.00 | US$6.13 | 7 |
| Feb ’24 | US$17.34 | US$22.07 +27.3% | 10.6% | US$26.00 | US$18.50 | US$9.20 | 7 |
| Jan ’24 | US$17.64 | US$22.00 +24.7% | 11.6% | US$26.00 | US$17.00 | US$10.49 | 8 |
| Dec ’23 | US$18.90 | US$22.00 +16.4% | 11.6% | US$26.00 | US$17.00 | US$12.13 | 8 |
| Nov ’23 | US$14.67 | US$22.29 +51.9% | 9.8% | US$26.00 | US$19.00 | US$13.33 | 7 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Elevance Health
US$92.9b
Operates as a health benefits company in the United States.
ELV
US$400.70
7D
-5.8%
1Y
-13.9%
CVS Health
US$66.9b
Provides health solutions in the United States.
CVS
US$56.05
7D
0.4%
1Y
-17.9%
Patterson Companies
US$1.7b
Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.
PDCO
US$20.90
7D
-0.7%
1Y
-34.7%